This map shows the geographic impact of C. Roux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Roux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Roux more than expected).
This network shows the impact of papers produced by C. Roux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Roux. The network helps show where C. Roux may publish in the future.
Co-authorship network of co-authors of C. Roux
This figure shows the co-authorship network connecting the top 25 collaborators of C. Roux.
A scholar is included among the top collaborators of C. Roux based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with C. Roux. C. Roux is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Papapoulos, Socrates E., C. Roux, Paula Dakin, et al.. (2015). Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension. Open Repository and Bibliography (University of Liège).2 indexed citations
6.
Papapoulos, Socrates E., Kurt Lippuner, C. Roux, et al.. (2014). EIGHT YEARS OF DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST FIVE YEARS OF THE FREEDOM EXTENSION. Open Repository and Bibliography (University of Liège).12 indexed citations
Papapoulos, Socrates E., Jacques P. Brown, R. Chapurlat, et al.. (2012). DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FOR 6 YEARS: RESULTS FROM THE FIRST 3 YEARS OF THE FREEDOM EXTENSION. Open Repository and Bibliography (University of Liège).2 indexed citations
9.
Roux, C., Jean‐Pierre Devogelaer, Donald Reid, et al.. (2008). Effect of Zoledronic Acid (Single 5-mg Infusion) on Lumbar Spine Bone Mineral Density Versus Oral Risedronate (5 mg/day) Over 1 Year in Subgroups of Patients Receiving Glucocorticoid Therapy.. Journal of Bone and Mineral Research. 23.1 indexed citations
10.
Bruyère, Olivier, et al.. (2007). Strontium ranelate prevents spine osteoarthritis progression in patients with prevalent spinal osteoarthritis. Open Repository and Bibliography (University of Liège).
Kouamé, B., et al.. (2003). [Therapeutic approaches for omphalocele in developing countries: experience of Central University Hospital of Yopougon, Abidjan, Côte d'Ivoire].. PubMed. 96(4). 302–5.6 indexed citations
13.
Meunier, Pierre J., C. Roux, S. Ortolani, et al.. (2002). Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis.. Osteoporosis International. 13(6). 521–522.29 indexed citations
14.
Geusens, P., H Zippel, Bensen Wg, et al.. (2001). Effect of risedronate on the risk of hip fracture in elderly women.. Ghent University Academic Bibliography (Ghent University).11 indexed citations
15.
Reginster, Jean‐Yves, et al.. (2001). Prevention of early postmenopausal bone loss by strontium ranelate : a randomised, two-year, double-blind, placebo-controlled trial. Open Repository and Bibliography (University of Liège).1 indexed citations
16.
Alexandersen, Peter, Anne Toussaint, Jean‐Yves Reginster, et al.. (2000). Ipriflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women. Open Repository and Bibliography (University of Liège).1 indexed citations
17.
Adachi, Jonathan D., C. Roux, P Pitt, et al.. (2000). A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. Lara D. Veeken. 27. 2424–2431.25 indexed citations
18.
Reginster, Jean‐Yves, et al.. (1999). Safety of strontium ranelate in prevention of postmenopausal bone loss - a double-blind, prospective, placebo-controlled study. Open Repository and Bibliography (University of Liège).3 indexed citations
19.
Miller, P. D., C. Roux, Michael R. McClung, et al.. (1999). Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. Open Repository and Bibliography (University of Liège).6 indexed citations
20.
Reginster, Jean‐Yves, et al.. (1998). Role of the Strontium Ranelate in the prevention of early postmenopausal bone loss : a double-blind, prospective, randomized, placebo-controlled study. Open Repository and Bibliography (University of Liège).3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.